PharmacoEconomics

, Volume 9, Issue 6, pp 535–559

Canadian Guidelines for Economic Evaluation of Pharmaceuticals

  • George W. Torrance
  • David Blaker
  • Allan Detsky
  • Wendy Kennedy
  • Francois Schubert
  • Devidas Menon
  • Peter Tugwell
  • Richard Konchak
  • Eleanor Hubbard
  • Theresa Firestone
Special Article

Summary

In 1994, p]Canada became the second country to release national guidelines for the economic evaluation of pharmaceuticals. The guidelines were developed over a period of 18 months through an elaborate process of broad consultation with a wide variety of relevant stakeholders. The intent of the guidelines is to provide guidance to doers and users of studies, by laying out the general ‘state of the art’ regarding methods, and by providing specific methodological advice on many matters. The aim is to improve the scientific quality and integrity of studies, and to enhance consistency and comparability across studies.

This article presents the Canadian guidelines, both in summary and in detail. Because the techniques of economic evaluation are widely applicable beyond pharmaceuticals, the guidelines will be of interest to researchers and decision makers in all fields of healthcare. Because the methods are not country specific, the guidelines will be of interest to those in other countries as well as in Canada.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Australian Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including major submissions involving economic analyses. Canberra: Australian Government Pubishing Service, 1995Google Scholar
  2. 2.
    Schubert F. Canadian collaborative workshop on pharmacoeconomics. Princeton (NJ): Excerpta Medica, Inc., 1993Google Scholar
  3. 3.
    Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals, lst ed. Ottawa: CCOHTA, 1994Google Scholar
  4. 4.
    Weinstein MC. Principles of cost-effective resource allocation in health care organizations. Int J Technol Assess Health Care 1990; (1): 93–103CrossRefGoogle Scholar
  5. 5.
    Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987Google Scholar
  6. 6.
    Detsky AS, Naglie IG. A clinician’s guide to cost-effectiveness analysis. Ann Intern Med 1990; 113 (2): 147–154PubMedGoogle Scholar
  7. 7.
    Bootman JL, Townsend RJ, McGhan WF, editors. Principles of pharmacoeconomics. Cincinnati: Harvey Whitney Books Company, 1991Google Scholar
  8. 8.
    Drummond MF, Torrance GW, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993; 37 (1): 33–40PubMedCrossRefGoogle Scholar
  9. 9.
    Miller GA. The magical number seven plus or minus two: some limits on our capacity to process information. Psychol Rev 1956; 63 (2): 81–97PubMedCrossRefGoogle Scholar
  10. 10.
    Johannesson M, Jonsson B. Economic evaluation in health care: is there a role for cost-benefit analysis? Health Policy 1991; 1 (1): 1–23CrossRefGoogle Scholar
  11. 11.
    Winston WL. Operations research: applications and algorithms. Boston: PWS-Kent Publishing Co., 1991Google Scholar
  12. 12.
    Culyer AJ. The normative economics of health care finance and provision. Oxford Rev Econ Policy 1989; (1): 34–58CrossRefGoogle Scholar
  13. 13.
    Culyer AJ. Commodities, characteristics of commodities, characteristics of people, utilities and the quality of life. In: Baldwin S, Godfrey C, Propper C, editors. Quality of life: perspectives and policies. London: Routledge, 1989; 9–27Google Scholar
  14. 14.
    Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. NBER Working Paper No. 4164. Cambridge (MA): National Bureau of Economic Research, 1992Google Scholar
  15. 15.
    Tugwell P, Bennett K, Sackett D. The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions. J Chronic Dis 1985; 38 (4): 339–351PubMedCrossRefGoogle Scholar
  16. 16.
    Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989; 5 (4): 559–575PubMedCrossRefGoogle Scholar
  17. 17.
    Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making 1989; (2): 142–149CrossRefGoogle Scholar
  18. 18.
    Mehrez A, Gafni A. The healthy-years equivalents: how to measure them using the standard gamble approach. Med Decis Making 1991; 11 (2): 140–146PubMedCrossRefGoogle Scholar
  19. 19.
    Mehrez A, Gafni A. Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs). PharmacoEconomics 1992; 1 (5): 338–345PubMedCrossRefGoogle Scholar
  20. 20.
    Buckingham K. A note on HYE (Healthy Years Equivalent). J Health Econ 1993; 12 (3): 301–309PubMedCrossRefGoogle Scholar
  21. 21.
    Culyer AJ, Wagstaff A. QALYs (quality-adjusted life-years) ver- sus HYEs (healthy years equivalents). J Health Econ 1993; 1 (3): 311–323CrossRefGoogle Scholar
  22. 22.
    Gafni A, Birch S, Mehrez A. Economics, health and health economics: HYEs (healthy-years equivalent) versus QALYs (quality-adjusted life-year). J Health Econ 1993; 12 (3): 325–339PubMedCrossRefGoogle Scholar
  23. 23.
    Fryback DG. QALYs, HYEs, and the loss of innocence [editorial]. Med Decis Making 1993; 13 (4): 271–272PubMedCrossRefGoogle Scholar
  24. 24.
    Johannesson M, Pliskin JS, Weinstein MC. Are healthy-year equivalents an improvement over quality-adjusted life years? Med Decis Making 1993; 13 (4): 281–286PubMedCrossRefGoogle Scholar
  25. 25.
    Mehrez A, Gafni A. Healthy-years equivalents versus quality-adjusted life years: in pursuit of progress. Med Decis Making 1993; 13 (4): 287–292PubMedCrossRefGoogle Scholar
  26. 26.
    Von Neumann J, Morgenstern O. Theory of games and economic behaviour. Princeton (NJ): Princeton University Press, 1953Google Scholar
  27. 27.
    Patrick DL, Erickson P. Health status and health policy: quality of life in health care evaluation and resource allocation. New York: Oxford University Press, 1993Google Scholar
  28. 28.
    Feeny DH, Torrance GW, Goldsmith CH, et al. A multi-attribute approach to population health status. Proceedings of the Social Statistics Section. Session IX: measuring health status: survey-based approaches. Alexandria (VA): American Statistical Association, 1994: 161–166Google Scholar
  29. 29.
    Furlong W, Torrance GW, Feeny D, et al. McMaster health utilities index of health-related quality of life [abstract]. Qual Life Res 1994; 3: 76–77Google Scholar
  30. 30.
    Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res 1988; 23 (2): 203–235PubMedGoogle Scholar
  31. 31.
    Rosser R, Kind P. A scale of valuations of states of illness: is there a social consensus? Int J Epidemiol 1978; 7 (4): 347–358PubMedCrossRefGoogle Scholar
  32. 32.
    EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16 (3): 199–208CrossRefGoogle Scholar
  33. 33.
    Essink-Bot ML, Stouthard ME, Bonsel GJ. Generalizability of valuations on health states collected with the EuroQol questionnaire. Health Econ 1993; 2 (3): 237–246PubMedCrossRefGoogle Scholar
  34. 34.
    Gafni A. Willingness-to-pay as a measure of benefits: relevant questions in the context of public decision making about health care programs. Med Care 1991; 29 (12): 1246–1252PubMedCrossRefGoogle Scholar
  35. 35.
    Labelle RJ, Hurley JE. Implications of basing health-care resource allocations on cost-utility analysis in the presence of externalities. J Health Econ 1992; 11 (3): 259–277PubMedCrossRefGoogle Scholar
  36. 36.
    Thompson MS. Willingness to pay and accept risks to cure chronic disease. Am J Public Health 1986; 76 (4): 392–396PubMedCrossRefGoogle Scholar
  37. 37.
    Johannesson M. Economic evaluation of lipid lowering: a feasibility test of the contingent valuation approach. Health Policy 1992; 2 (3): 309–320CrossRefGoogle Scholar
  38. 38.
    Johannesson M. Economic evaluation of hypertension treatment. Int J Technol Assess Health Care 1992; 8 (3): 506–523PubMedCrossRefGoogle Scholar
  39. 39.
    Feeny D, Barr RD, Furlong W, et al. Quality of life of the treatment process in pediatric oncology: an approach to measurement. In: Osoba D, editor. Effect of cancer on quality of life. Boca Raton (FL): CRC Press, 1991: 73–88Google Scholar
  40. 40.
    Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis 1978; 3 (11): 697–704CrossRefGoogle Scholar
  41. 41.
    Llewellyn-Thomas HA, Sutherland HJ, Thiel EC. Do patients’ evaluations of a future health state change when they actually enter that state? Med Care 1993; 3 (11): 1002–1012CrossRefGoogle Scholar
  42. 42.
    Williams A. Ethics and efficiency in the provision of health care. In: Bell JM, Mendus S, editors. Philosophy and Medical Welfare. Cambridge: Cambridge University Press, 1988: 111–126Google Scholar
  43. 43.
    Loomes G, McKenzie L. The use of QALYs in health care decision making. Soc Sci Med 1989; 28 (4): 299–308PubMedCrossRefGoogle Scholar
  44. 44.
    Gafni A, Birch S. Equity considerations in utility-based measures of health outcomes in economic appraisals: an adjustment algorithm. J Health Econ 1991; 10 (3): 329–342PubMedCrossRefGoogle Scholar
  45. 45.
    Broome J. Utility. Econ Phil 1991; 7 (1): 1–12CrossRefGoogle Scholar
  46. 46.
    Broome J. QALYs. J Publ Econ 1993; 50 (2): 149–167CrossRefGoogle Scholar
  47. 47.
    Sen A. Utility: ideas and terminology. Econ Phil 1991; 7 (2): 277–283CrossRefGoogle Scholar
  48. 48.
    Richardson J. Cost-utility analyses: what should be measured — utility, value or healthy years equivalents? Working Paper No. 9. Fairfield (Victoria, Australia): Public Sector Management Institute, Monash University, 1989Google Scholar
  49. 49.
    Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296 (13): 716–721PubMedCrossRefGoogle Scholar
  50. 50.
    Keeler EB, Cretin S. Discounting of life-saving and other non-monetary effects. Manag Sci 1983; 29 (3): 300–306CrossRefGoogle Scholar
  51. 51.
    Parsonage M, Neuburger H. Discounting and health benefits. Health Econ 1992; 1 (1): 71–76PubMedCrossRefGoogle Scholar
  52. 52.
    Australian Commonwealth Department of Health, Housing and Community Services. Manual of resource items and their associated costs. Canberra: Commonwealth Department, 1992Google Scholar
  53. 53.
    Gafni A, Torrance GW. Risk attitude and time preference in health. Manag Sci 1984; 30 (4): 440–451CrossRefGoogle Scholar
  54. 54.
    Lipscomb J. Time preference for health in cost-effectiveness analysis. Med Care 1989; 27 (3 Suppl.): S233–S253PubMedCrossRefGoogle Scholar
  55. 55.
    Krahn M, Gafni A. Discounting in the economic evaluation of health care interventions. Med Care 1993; 31 (5): 403–418PubMedCrossRefGoogle Scholar
  56. 56.
    Fuchs VR. Time preference and health: an exploratory study. In: Fuchs VR, editor. Economic aspects of health. Chicago: University of Chicago Press, 1982: 93–120Google Scholar
  57. 57.
    Harvey CM. The reasonableness of non-constant discounting. J Publ Econ 1994; 53: 31–51CrossRefGoogle Scholar
  58. 58.
    Jenkins GP. The public-sector discount rate for Canada: some further observations. Can Public Policy Analyse Politiques 1981; 7 (3): 399–407Google Scholar
  59. 59.
    Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Toronto: Ontario Ministry of Health, 1994Google Scholar

Copyright information

© Adis Data Information BV 1996

Authors and Affiliations

  • George W. Torrance
    • 1
    • 2
    • 3
    • 4
  • David Blaker
    • 5
  • Allan Detsky
    • 6
  • Wendy Kennedy
    • 7
  • Francois Schubert
    • 8
    • 9
  • Devidas Menon
    • 10
  • Peter Tugwell
    • 11
  • Richard Konchak
    • 12
  • Eleanor Hubbard
    • 13
  • Theresa Firestone
    • 14
  1. 1.Centre for Health Economics and Policy AnalysisMcMaster UniversityHamiltonCanada
  2. 2.Centre for Evaluation of MedicinesSt Joseph’s HospitalHamiltonCanada
  3. 3.Department of Clinical Epidemiology and BiostatisticsMcMaster UniversityHamiltonCanada
  4. 4.Department of Management ScienceMcMaster UniversityHamiltonCanada
  5. 5.Health CanadaOttawaCanada
  6. 6.Division of General Internal Medicine and Clinical EpidemiologyThe Toronto Hospital, University of TorontoTorontoCanada
  7. 7.Groupe de Recherche Interdisciplinaire en Sante (GRIS)University of MontrealMontrealCanada
  8. 8.Glaxo-WellcomeKirklandCanada
  9. 9.Pharmaceutical Manufacturers Association of CanadaOttawaCanada
  10. 10.Canadian Coordinating Office for Health Technology AssessmentOttawaCanada
  11. 11.Department of MedicineUniversity of OttawaOttawaCanada
  12. 12.Patented Medicine Prices Review BoardOttawaCanada
  13. 13.Nova Scotia Department of HealthHalifaxCanada
  14. 14.Ontario Ministry of HealthTorontoCanada

Personalised recommendations